上述数据使用的会计准则为US-GAAP。$Adaptimmune Therapeutics (ADAP.US)$ is scheduled to release its financial results post-market on November 13 ET.
Earnings Preview
Analysts estimate $Adaptimmune Therapeutics (ADAP.US)$ to post revenue of USD20.49M for 2024Q3, up 179.94% YOY;
EPS is estimated to be USD-0.08, Net Loss Widened 160.54% YoY.
The accounting standard used for the above data is US-GAAP.
Note:
US-listed companies have full discretion in choosing their accounting year-end date, without being subject to any mandatory requirements. Consequently, every financial reporting period can act as the annual report cutoff date for a company, rather than following a natural calendar year as the fiscal year.
Typically, companies host conference call around the date of the financial report publication to discuss the most recent financial results and operational performance while engaging with investors, analysts, and media. Investors are free to attend either through offline meetings or online conference calls.
